Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, southern India

Journal of the International Association of Physicians in AIDS Care

Volumn 8, Issue 5, 2009, Pages 323-327

  Iqbal, H Syed ^a   Solomon, Sunil S ^a   Madhavan, Vidya ^a   Solomon, Suniti ^a   Balakrishnan, P ^a  

^a The Voluntary Health Services Chennai   (India)

Author keywords

HIV 1; HIV 1 polymorphism; injecting drug users; primary drug resistance

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ABACAVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DIDANOSINE; DRUG DERIVATIVE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD; CROSS-SECTIONAL STUDY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MALE; MUTATION; SUBSTANCE ABUSE;

ADENINE; ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DEOXYCYTIDINE; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INDIA; MALE; MUTATION; PHOSPHONIC ACIDS; POLYMORPHISM, GENETIC; RNA, VIRAL; SAQUINAVIR; STAVUDINE; SUBSTANCE ABUSE, INTRAVENOUS; ZIDOVUDINE;

EID: 75349114190     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109709341854     Document Type: Article

References (19)

1. UNAIDS/WHO / Report on the global AIDS epidemic. Status of the global HIV epidemic; 2008. http://www.unaids.org. Accessed August, 2008.
2. National AIDS Control Organization (NACO), India. HIV sentinel surveillance and HIV estimation in India 2007: a technical brief ; 2009. http://www.nacoonline.org/upload/Publication/M&E%20Surveillance,%20Research/ HIV%20Sentinel%20Surveillance%20and%20HIV%20Estimation%202007- A%20Technical%20Brief.pdf. Accessed February, 2009.
3. Shah B., Walshe L., Saple DG, et al. Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis. 2007 ; 44 (9). 1235-1244. (Pubitemid 46651251)
4. Sunil S., Balakrishnan P., Shetty N., et al. Prevalence of treatment failure and drug resistance among treatment-experienced hiv-1-infected individuals at a tertiary HIV referral center in South India. 14th Conference on Retroviruses and Opportunistic Infections ; February 25-28, 2007 ; Los Angeles, CA, poster 647.
5. National AIDS Control Organization (NACO), India. HIV/AIDS epidemiological surveillance & estimation report for the year 2005; 2006. http://www.nacoonline.org/fnlapil06rprt.pdf. Accessed February, 2008.
6. Solomon SS, Srikrishnan AK, Mehta SH, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr. 2008 ; 49 (3). 327-332.
7. Balakrishnan P., Kumarasamy N., Kantor R., et al. HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. AIDS Res Hum Retroviruses. 2005 ; 21 (4). 301-305. (Pubitemid 40632362)
8. Shafer RW, Rhee SY, Pillay D., et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007 ; 21 (2). 215-223. (Pubitemid 46036930)
9. Kantor R., Katzenstein DA, Efron B., et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005 ; 2 (4). e112.
10. Baxter JD, Schapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor Tipranavir. J Virol. 2006 ; 80 (21). 10794-10801. (Pubitemid 44628925)
11. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998 ; 338 (13). 853-860.
12. Pujari S., Patel A., Joshi SR, et al. Guidelines for use of antiretroviral therapy for HIV infected individuals in India (ART guidelines 2008). J Assoc Physicians. 2008 ; 56: 339-348, 353-371.
13. Stanford University. HIV drug resistance database. A curated database designed, to represent store and analyze the divergent forms of data underlying HIV drug resistance. Mutation List Analysis. http://hivdb6.stanford.edu/asi/ deployed/hiv-central.pl?program=hivdb&action=showMutationForm. Accessed April 15, 2008.
14. Kozal MJ, Amico KR, Chiarella J., et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr. 2005 ; 40 (1). 106-109. (Pubitemid 41233214)
15. Salomon H., Wainberg MA, Brenner B., et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS. 2000 ;14 (2). F17 - F23.
16. Sethi AK, Celentano DD, Gange SJ, Gallant JE, Vlahov D., Farzadegan H. High-risk behavior and potential transmission of drug-resistant HIV among injection drug users. J Acquir Immune Defic Syndr. 2004 ; 35 (5). 503-510. (Pubitemid 38420659)
17. Maia Teixeira SL, Bastos FI, Hacker MA, Guimarães ML, Morgado MG Trends in drug resistance mutations in antiretroviral-naïve intravenous drug users of Rio de Janeiro. J Med Virol. 2006 ; 78 (6). 764-769.
18. Liao L., Xing H., Li X., et al. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. AIDS Res Hum Retroviruses. 2007 ; 23 (8). 1062-1065. (Pubitemid 47492349)
19. Kantor R., Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 2003 ; 5 (1). 25-35. (Pubitemid 36873892)